DiaCarta Receives CE/IVD for its New COVID 19 test that Identifies Delta Plus and New Variants
UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world.
DiaCarta Q&A: Liquid Biopsy for Early Cancer Detection
DiaCarta is initiating a large-scale clinical development program, which will monitor cfDNA levels to determine early treatment outcomes of systemic therapy in all types of stage IV cancer.
DiaCarta’s Novel XNA Technology Rapidly Detects Raging New SARS-CoV-2 Variants
UF Innovate | Sid Martin Biotech alum DiaCarta Inc. announced the publication of a study to rapidly detect new COVID-19 variants in MedRxiV.
Sid Martin Biotech Alum DiaCarta’s Biomarker Algorithm Predicts Response and Outcome of Chemotherapy
UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostics company with proprietary technologies for the development of novel liquid biopsy oncology tests, announced the publication of a study in Nature Scientific Reports that demonstrates the company's cfDNA biomarker algorithm could function as a prognostic biomarker and efficacy predictor for non-small cell lung cancer (NSCLC) patients.
DiaCarta Gets FDA Emergency Use Authorization for Coronavirus PCR Test
UF Innovate | Sid Martin Biotech alum DiaCarta, a molecular diagnostic firm, has obtained the Emergency Use Authorization from the US Food... Read More
DiaCarta SARS-CoV-2 Test Kit Receives CE Mark
Molecular diagnostic firm and UF Innovate | Sid Martin Biotech alum DiaCarta said that its QuantiVirus SARS-CoV-2 test recently received the CE... Read More
